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RÉSUMÉ
Les oxydants infusés avec la nutrition parentéral (NP) néonatale induisent une mo-
dification du métabolisme des lipides et du glucose, donnant lieu à l’âge adulte à un
phénotype de carence énergétique (faible poids, baisse de l’activité physique). L’hypo-
thèse qu’une diète précoce riche en glucose prévient ces symptômes plus tard dans la
vie, fut évalué chez le cobaye par un ANOVA en plan factoriel complet à deux fac-
teurs (p < 0.05) : NP du jour 3 à 7, suivit d’une nourriture régulière (chow) (NP+)
vs. chow à partir du 3ième jour (NP-), combiné avec une eau de consommation enri-
chie en glucose (G+) ou non (G-) à partir de la 3ième semaine. Les paramètres suivant
ont été mesurés à l’âge de 9 semaine: taux de croissance, activité physique, activité de
phosphofructokinase-1 et glucokinase (GK), niveau hépatique de glucose-6-phosphate
(G6P), glycogène, pyruvate et potentiel redox du glutathion, poids du foie, glycémie, to-
lérance au glucose, concentrations hépatiques et plasmatiques en triacylglycérides (TG)
et cholestérol. Le groupe G+ (vs. G-) avait un taux de croissance plus bas, une activité
de GK et une concentration en G6P plus élevée, et un potentiel redox plus bas (moins
oxydé). Le niveau plasmatique de TG était moins élevé dans le groupe NP+ (vs. NP-).
Les traitements n’eurent aucun effet sur les autres paramètres. Ces résultats suggèrent
qu’indépendamment de la NP, une alimentation riche en glucose stimule la glycolyse et
déplace l’état redox vers un statut plus réduit, mais ne surmonte pas les effets de la NP
sur le phénotype physique de carence énergétique.
Mots-clés: Nouveau-né, nutrition parentérale, métabolisme du glucose, potentiel
redox, programmation métabolique, cobaye, impact à long terme.
ABSTRACT
Neonatal exposure to oxidant molecules from total parenteral nutrition (TPN) alters
future lipid and glucose metabolism, resulting in an energy deficient phenotype characte-
rized by lower body weight and physical activity. Using a guinea-pig model, the hypothe-
sis that early diet supplementation with glucose could overcome such symptoms at week
9 of age was tested in a two-factor full-factorial ANOVA design (p< 0.05): TPN day 3-7,
chow thereafter (TPN+) vs. chow from day 3 (TPN-), combined with glucose-enriched
diet from week 3 (G+) vs. plain chow throughout (G-). The growth rate, physical acti-
vity, phosphofructose kinase-1 and glucose kinase (GK) activities, glucose-6-phosphate
(G6P), glycogen and pyruvate concentrations, relative liver weight, fasting blood glu-
cose, glucose tolerance, hepatic and plasma triacylglyceride and cholesterol levels, in-
dividual glutathione levels and GSH/GSSG-based redox potential were determined at 9
weeks. Glucose supplementation (vs. the lack thereof) resulted in a lower growth rate,
higher GK activity, and higher G6P concentration at week 9. Plasma triacylglycerides
at week 9 were lower in TPN+ (vs. TPN-) subjects. Hepatic GSH/GSSG-derived redox
potential shifted to a more reduced state in G+ (vs. G-) subjects. No other parameters
showed significant differences. Independently of TPN, an early glucose-rich diet stimu-
lated the glycolysis pathway, shifted the redox potential towards a more reduced status ;
however, it did not overcome the effects of TPN on future physical and metabolic phe-
notype.
Keywords: Neonates, total parenteral nutrition, glucose metabolism, redox po-
tential, metabolic programming, guinea pig, long-term impact.
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CHAPITRE 1
LITERATURE REVIEW
Premature birth occurs in 12.5% of deliveries in the United States and 8% in Canada
(2006-2007) [1]. Many of these infants do not develop any prematurity problems since
they are born only a few weeks prior to full term delivery; however, others are at risk
of serious complications throughout their lifetime. For instance, infants born before 28
weeks of gestation are at high risk for chronic diseases such as diabetes and cardiovascu-
lar disorders [2–9]. Epidemiological evidence demonstrates that a suboptimal gestational
and postnatal environment, including nutrition, plays a key role in the associated increase
of metabolic diseases observed in adults [10–13].
Infants born before 28 weeks of gestation cannot be fed enterally [3, 6, 7] due to the
immaturity of their gastrointestinal tract [10–17]. Intravenous nutritive support - or total
parenteral nutrition (TPN) - is therefore essential for their growth and development. Un-
fortunately, TPN formulations are contaminated with oxidant molecules [18–21], mainly
hydrogen peroxide (H2O2) [22]. Such peroxides are the end products of reactions bet-
ween oxygen dissolved in the TPN solution and various electron donors, such as ascor-
bate, amino acids, and lipids [18, 19, 22–25]. Given that such reactions are catalyzed
by photo-excited riboflavin, a vitamin present in TPN formulations [26, 27], protection
against ambient light can halve the peroxide concentrations in TPN solutions [28]. Labo-
rie S et al. observed that the use of TPN not afforded full protection from light was corre-
lated with an increase in peroxide concentrations in the urine of premature infants [29].
Their observation suggests that this population is unable to quench this oxidant load,
possibly as a result of their immature antioxidant defense system [29–34]. In the short-
term, infusion of TPN or a solution bearing a similar quantity of peroxides during the
neonatal period is associated with a perturbation of lipid and glucose metabolism [35];
however, the long-term impacts of delivering such oxidant molecules through TPN infu-
sions remain unclear.
2"The developmental origin of adult health and disease hypothesis" affirms that the
origin of several adult metabolic diseases (e.g. cardiovascular diseases, type II diabetes,
and hypertension) can be traced back to fetal and postnatal life [36–38]. In an animal
model of neonatal parenteral nutrition, Kleiber N et al. demonstrated that early intrave-
nous exposure to peroxides, as generated in this nutritive solution, induces permanent
modifications in the metabolism of lipids and glucose later in life [35]. They sugges-
ted that peroxides contaminating TPN solutions permanently modify the metabolism of
energy, thus perturbing growth rate, physical activity, and metabolic responses later in
life [35]. The phenotype of animals thus afflicted was one of energy deficiency [35].
Several studies support the notion that one mechanism by which postnatal nutrition
affects the long-term outcome is developmental programming [9, 39]. Using a guinea
pig model of neonatal parenteral nutrition, the present study was designed to investigate
the long-term (eight weeks after ending TPN) effects of a 4-day neonatal exposure (Day
3 to 7 of life) to TPN, combined with an early diet enriched in glucose (Week 3 to 9
of life) on their glucose metabolism 8 weeks after stopping TPN (i.e., 9 weeks from
birth). The introduction of glucose to the diet was intended to assess if high caloric nu-
trient enrichment of the diet could overcome the energy deficiency previously observed
by Kleiber N et al. [35].The following sections briefly explain the notion of develop-
mental programming and oxidative stress observed in neonates in relation to parenteral
nutrition.
1.1 Concept of Developmental Programming
The association between early life events and the development of adult diseases has
recently become widely recognized [9]. This association is mainly attributed to the pro-
gramming concept stemming from Barker’s hypothesis of "developmental origin of adult
health and disease" [9]. Programming, or the modulation of the gene expression, repre-
sents the ability to adapt to environments encountered during development [9]. Although
3the short-term gains are adaptation to the environment, the long-term costs are permanent
changes in the character of tissues [40] and in gene expression profiles [9].
1.2 Risk Factors in Postnatal Programming
Several risk factors hinder postnatal programming. One such factor is the infants’
size at birth. Barker has shown that there exists a causality between low birth weight and
diseases that may generate adult coronary heart disease as well as metabolic disorders
such as hypertension, type II diabetes, and hyperlipidemia [2, 4, 5, 8]. It is well establi-
shed that the correlation between small birth size in neonates kept in the NICU (Neonatal
Intensive Care Unit) and impaired glucose regulation later in life is much greater than
that for individuals born at term [41].
The second factor is postnatal nutrition and dietary composition. Preterm infants are
at risk of postnatal over-nutrition and rapid catch-up growth [39, 42]. Kashyap S et al.
observed that high non-protein energy feeding of low birth weight infants resulted in a
weight increase due to body fat rather than lean body mass [43]. However, high-protein
diets may induce the proliferation of adipose formation and obesity later in life [44]. The
Dortmund Nutritional and Anthropometric Longitudinally Designed Study (DONALD),
a longitudinal study of 216 individuals, evaluated the associations between added sugar
intake during early childhood and body mass index (BMI) and body fat at 7 years of
age [45]. The study showed that while a higher total added sugar intake during the first
year of age was correlated with a lower BMI at 7 years of age, the same added sugar
intake during the second year of life was associated with a higher BMI at 7 years of age.
However, no associations were observed with the percentage of body fat [45]. Kleiber N
et al. demonstrated in guinea pigs the relation between early TPN and a decrease in level
of plasma triglyceride later in life [35]. Various dietary regimens may likewise have an
effect on organ development. Rat pups with high protein intake showed greater growth
rate in the short term, as well as insulin resistance [46]. In the rat pups-in-the cup mo-
del with high carbohydrate intake, alterations in adult metabolism, along with obesity,
4were observed [47–54]. In this population, modification in individuals’ insulin secretory
capacity increased hexokinase activity and insulin biosynthesis [47–54]. In this model,
a high carbohydrate diet in early life augments the quantity of pancreatic islets [47–54].
Furthermore, evidence suggests that breastfeeding during the postnatal period prevents
the development of metabolic diseases in full term infants. Later in life, breastfed infants
have lower blood pressure, total cholesterol, and prevalence of overweightness and obe-
sity [55–57].
The third risk factor is postnatal growth rate. It has been observed that in low birth
weight infants, rapid postnatal growth rate over the first 4 months leads to a greater body
weight later in life [58]. Animal studies have demonstrated the effect of postnatal growth
rate in metabolic diseases. In the rat model, accelerated growth altered the metabolic pa-
rameters in response to a high-fat diet, as well as increased weight and percentage of
body fat [59]. These observations confirm the Lucas hypothesis of "accelerated growth",
which illustrates the connection between faster early postnatal growth in preterm infants
and an increased risk of the metabolic syndrome indicators [60, 61].
Another risk factor in programming is oxidative stress (OS). Oxidative stress pro-
gramming occurs directly through the modulation of gene expression or indirectly through
the oxidation of lipids, proteins, and DNA [62]. In preterm infants, oxidative stress may
increase the prevalence of the metabolic syndrome, type II diabetes, and several other
metabolic disorders later in life [35–38]. Kleiber N et al. have shown in the guinea pig
model that exposure to oxidative stress early in life effects a permanent modification in
the programming of lipid and glucose metabolism, resulting in energy deficiency obser-
ved later in life [35]. Such modifications in the guinea pig animal model had long-term
effects on the animals’ growth and physical activity [35].
51.3 Oxidative Stress
Reactive oxygen species (ROS) are byproducts of mitochondrial electron transport in
the cellular respiratory chain. Moreover, they are inevitable byproducts of several cellu-
lar and extracellular redox reactions [62–64]; hence, they are constantly produced within
the organism. In moderate concentrations, ROS regulates enzymes and redox-sensitive
gene expression [63, 65, 66]. The antioxidant system sustains the homeostasis of ROS
inside the cells.
Conversely, an imbalance between ROS load or its generation and antioxidant de-
fenses within the cell, known as oxidative stress, can cause serious cellular damage.
Superfluous amounts of oxidants may react with cellular macromolecules, thereby in-
ducing lipid peroxidation and modifications of proteins and DNA [67, 68]. Biological
activities generally decrease with the attack of oxidized products of ROS, resulting in
metabolic dysregulation and an alteration in cellular signaling functions [43, 53]. Stu-
dies have demonstrated that premature infants are more prone to oxidative stress due
to environmental, biological, and nutritional conditions, such as early postnatal use of
parenteral nutrition [18, 19, 22–24].
1.4 Total Parenteral Nutrition
Parenteral nutrition was first introduced in 1967 to human infants suffering from ex-
treme short bowel syndrome [69]. Today, parenteral nutrition refers to the administration
of supplemental intravenous nutrients via a continuous infusion through a peripheral or
central vein [68]. Since it contains all the essential nutrients for metabolic requirements
and growth, it was named total parenteral nutrition (TPN) [11, 70]. This intravenous so-
lution includes glucose, amino acids, lipids, vitamins, and trace elements [11, 70]. In
North America, TPN is administered without adequate light protection [71, 72].
61.5 Total Parenteral Nutrition as a Source of Oxidant Molecules
Silvers KM et al. showed that exposure to light decreases the levels of antioxidant
vitamins (i.e. vitamins A, C, and E) in the TPN solution [25]. The absence of full photo
protection also increases or catalyzes the generation of byproducts of nutrient oxida-
tion such as hydrogen peroxide (H2O2) [19], lipid peroxides [18], as well as aldehydes,
especially 4-hydroxy-2-nonenal [24], and ascorbylperoxide [23]. These products are ge-
nerated by a reaction between oxygen dissolved in the solution and different electron
donors such as ascorbate, amino acids, or lipids [20, 21, 73]. Lavoie JC et al. demons-
trated that the H2O2 represents approximately 80% of the total peroxides generated in
TPN solutions [22]. Given that ascorbate is the prime electron donor, the main source of
peroxides is the multivitamin preparation [22, 26, 27]. Furthermore, multivitamin prepa-
rations used in parenteral nutrition also contains riboflavin, a photo-sensitive component
which acts as a catalyst in the photo-oxidation of nutrients [26, 27]. Lavoie JC et al. sho-
wed a rise in urinary peroxide concentration in newborn premature infants who received
TPN exposed to light [29]. The study confirms premature infants’ incomplete capacity
to scavenge peroxides [29]. This fact may be related to the immaturity of the antioxidant
defenses of preterm newborns. Indeed, several studies have demonstrated that newborn
antioxidant defenses increased in function of the age of gestation. Frank L et al. [74, 75]
showed that activities of antioxidant enzymes such as catalase, glutathione peroxidase,
and superoxide dismutase increase in the last trimester of gestation. Lavoie JC et al. [76]
reported that the level of glutathione, the key antioxidant molecule, is directly propor-
tional to the gestational age. Therefore, this population is more prone to oxidative stress
due to the high oxidant load from TPN and their low antioxidant levels.
The impact of oxidative load from TPN cannot be adequately studied in premature
infants since appropriate control group, premature infants (<28 weeks of gestation) wi-
thout TPN, does not exist. Therefore, only a reduction of peroxides in TPN by light
protection can be done. However, light protection is difficult in clinical situations. The
few scientific teams who have studied the impact of oxidants infused with TPN have
7reported that the absence of light protection is associated with higher oxidative stress in
premature infants [27, 28], lower plasma triacylglycerol and blood glucose [35], lower
arterial blood pressure [77], and higher incidence of chronic lung diseases [27] in the
short term. No data is available on the long-term impact of light protection of TPN in
humans.
The guinea pig model of neonatal TPN has been developed in our laboratory to study
the impact of TPN compared to a control group without TPN. Several studies with this
animal model reported that TPN is related to oxidative stress in the lungs, blood and li-
ver [27, 28, 78, 79], hepatic steatosis [28], and higher plasma triacylglycerol levels [80].
One study demonstrated that the administration, in the first week of life, of either TPN
or a solution of H2O2 at a concentration equivalent to the total peroxides measured in the
TPN, both induced a perturbation of energy metabolism 12 to 13 weeks after cessation
of the infusion [35]. Compared to control groups, without TPN or peroxides, animals
infused with TPN or peroxides had a lower plasma triacylglycerol level, a lower glucose
tolerance, a lower body weight, and a lower propensity to spontaneous activity. We can
conclude from this study that TPN induced an energy deficiency later in life [35].
Following these observations in the guinea pig system, the present research with this
animal model was designed to explore the impact of a diet enriched in glucose, as a sup-
plemental source of calories, on glucose metabolism and physical phenotypes 8 weeks
after that the administration, or not, of TPN during their first week of life. The next sec-
tion provides an overview of glucose metabolism.
1.6 Glucose Metabolism Pathways
Carbohydrates such as glucose are important parts of our diet. Glucose is an impor-
tant source of energy for body cells. In animals and humans, glucose has three main fates
(figure 1.1) [81]:
8– It may be oxidized into pyruvate via the glycolysis pathway to provide ATP and
metabolic intermediates if the body and cells need energy [81].
– It may be stored as glycogen via the glycogenesis pathway if the body has excess
blood glucose [81].
– It may be oxidized via pentose phosphate pathway into ribose 5-phosphate for syn-
thesis of nucleic acids and NADPH for reductive reactions, especially glutathione
reduction [81].
FIGURE 1.1 – Major pathways of glucose in the body (adapted from Lehninger C [81]).
1.6.1 Overview of Glycolysis Pathway
Glycolysis, the first and central pathway of glucose catabolism, was discovered in
1897 by Eduard Buchner [81]. In glycolysis, a molecule of glucose is degraded in a se-
ries of enzyme-catalyzed reactions to yield two molecules of the three-carbon compound
pyruvate. During these sequential reactions of glycolysis, some of the free energy relea-
sed from glucose is conserved in the form of ATP and NADH. The breakdown of the
9six-carbon glucose into two molecules of the three-carbon pyruvate occurs in ten steps,
which can be categorized in two phases as illustrated in figure 1.2;
– The preparatory phase, in which glucose is phosphorylated and converted into
glyceraldehyde 3-phosphate.
– The pay off phase, in which glyceraldehyde 3-phosphate is oxidized into pyruvate,
while generating ATP and NADH.
To summarize, in the preparatory phase of glycolysis, the energy of ATP is invested,
raising the free-energy content of the intermediates, and the carbon chains of all the
metabolized hexoses are converted into a common product, glyceraldehyde 3-phosphate,
while in the payoff phase the desired energy is released [81].
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FIGURE 1.2 – Glycolysis pathway (adapted from Lehninger C [81]).
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The rate of glucose metabolism is adjusted by a complex interplay between ATP
consumption, NADH regeneration, and allosteric regulation of several glycolytic en-
zymes, including hexokinase, phosphofructokinase-1 (PFK-1), and pyruvate kinase, and
by second-to-second fluctuations in the concentration of key metabolites that reflect the
cellular balance between ATP production and consumption [81]. Neonatal exposure to
oxidant molecules has been noted to lead to permanent modification on the programming
of glycolysis, resulting in metabolic diseases later in life [35, 81]. The most important
modifications are lower phosphofructokinase activity, higher glucokinase activity, lower
blood glucose, lower glucose tolerance and lower hepatic and plasma triacylglycerol
concentrations [35]. Considering the origin of the "adult health and disease" hypothe-
sis, such a metabolic modification early in life holds several consequences for metabolic
disorders such as cardiovascular disease, type II diabetes and lower overall energy for
growth and development later in life [36–38]. In the present study, the effects of neona-
tal exposure to oxidant molecules, along with an early glucose supplementation, on the
programming of glycolysis was investigated. To ascertain if glucose has entered the gly-
colysis (vs. the glycogenesis or pentose phosphate) pathway, glucose 6-phosphate (G6P)
and pyruvate levels, as well as glucokinase (GK) and phosphofructokinase-1 (PFK-1)
activities, were measured. These glycolytic pathway catalysts are briefly discussed in
the next few sections.
1.6.1.1 Glucokinase (Hexokinase IV))
GK is the first key enzyme in glycolysis. It catalyzes the phosphorylation of glu-
cose substrate to glucose 6-phosphate (section 1.6.1.2). Glucokinase or hexokinase IV is
the hepatocyte form of hexokinase, which differs from other forms of hexokinase in its
kinetic and regulatory properties [82]. Such differences have the potential to fine-tune
metabolic rates. For example, the sensitivity of glucokinase, an allosteric enzyme [82],
to be inhibited by glucose 6-phosphate is different from that of other types of hexokinase
present in other tissues [73, 81]. Glucokinase has a lower affinity for glucose than the
other hexokinases. This enzyme plays a key role in the liver to maintain blood glucose
homeostasis by removing blood glucose for its transformation into glycogen (glycoge-
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nesis pathway) or pyruvate (glycolysis pathway), depending on the prevailing glucose
concentration [73]. Kleiber N et al. demonstrated that GK activity during guinea pigs’
first 13 weeks of life were greater when these were exposed to neonatal oxidative stress
caused by the oxidant load of TPN [35]. The present study focuses on the effects of
neonatal exposure to oxidant molecules on GK activity at guinea pigs’ ninth week of
life, and the effects of early glucose supplementation on this activity. In fact, one of the
aims of the present study is to demonstrate the probable relation between early glucose
supplementation and alteration of GK activity in animals exposed or not to TPN in their
first week of life.
1.6.1.2 Glucose 6- phosphate
Glucose 6-phosphate is glucose molecule phosphorylated on carbon 6 [83]. This
compound is very common in cells since almost the entire amount of glucose entering
a cell becomes phosphorylated in this way [83]. Glucose 6-phosphate initiates all of
the glucose metabolism pathways; glycolysis, glycogenesis, and the pentose phosphate
pathway [81, 84]. The phosphorylation of glucose is catalyzed by the enzyme hexokinase
in most cells and by glucokinase in liver cells.
1.6.1.3 Phosphofructokinase-1
PFK-1 is the next key enzyme in glycolysis. It phosphorylates fructose 6-phosphate
to produce fructose 1,6-bisphosphate [81, 85]. It has an allosteric regulatory role in the
body, thereby regulating the rate of glycolysis [81, 86–88]. Its activity increases when
ATP for cell requirements is depleted, and is inhibited under high levels of ATP or fatty
acids in the organ [81].
1.6.1.4 Pyruvate
Pyruvate is the final product of the glycolysis pathway, where one molecule of glu-
cose breaks down into two molecules of pyruvate. Through glycolysis, energy is released
; however, further energy may be obtained upon the pyruvate entering one of two cycles :
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(i) its conversion into acetyl-coenzyme A through the Krebs cycle or (ii) its conversion
into oxaloacetate through the citric acid cycle. Measurement of pyruvate as the final pro-
duct of the glycolysis pathway reveals the probability of the entrance of glucose into this
pathway [81].
1.6.2 Overview of Glycogenesis Pathway
The storage of glucose in the form of glycogen in the liver and other body tissues
occurs via a metabolic activity known as glycogenesis. In theory, it is defined as a pro-
cess in which glucose molecules are added to glycogen chains. Glycogenesis is activated
when the body is in a state of rest or during instances of high glucose levels in the blood.
Insulin activates this process to reduce blood sugar levels [81].
Glycogenesis contains two main steps. However, similar to the other glucose meta-
bolism pathways, initially glucose is converted into glucose 6-phosphate by the action of
glucokinase. Then, glucose 6-phosphate is converted into glucose 1,6-bisphosphate by
phosphoglucomutase and later into glucose 1-phosphate.
– The first step involves synthesis of UDP-glucose from glucose 1-phosphate in the
presence of UDP-glucose pyrophosphorylase. A hydrolytic process converts pyro-
phosphate to orthophosphate, making this step a non-reversible reaction [81, 89].
– Glycogen synthase catalyzes the linkage of the previously generated UDP-glucose
through a hydroxyl group in the glycogen molecule, forming α-1,4-glycosidic
link. This binding requires a protein like glycogenin which contains the glycogen
branching enzyme [81, 89].
In this study, the possibility of the entrance of glucose into the glycogenesis pathway
is investigated through the measurement of glycogen levels.
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FIGURE 1.3 – Pentose phosphate pathway in the body in connection with redox cycle
(adapted from Lehninger C [81]).
1.6.3 Overview of Pentose Phosphate Pathway
Althought glucose 6-phosphate is mostly converted into pyruvate through glycoly-
sis, G6P may enter an alternative catabolic pathway known as the pentose phosphate
pathway. This pathway (figure 1.3) contains two distinct phases: (i) the oxidative phase,
where NADPH is generated, and (ii) the non-oxidative synthesis of pentose [81]. In the
oxidative phase, two molecules of NADP+ are reduced to NADPH, using the energy
from the conversion of G6P into ribose 5-phosphate (figure 1.3). The ribose 5-phosphate
produced can be used in the synthesis of nucleotides and nucleic acids. Within cells
that are not using ribose 5-phosphate for biosynthesis, the nonoxidative phase recycles
six molecules of the pentose into five molecules of the hexose glucose 6-phosphate,
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allowing continued production of NADPH and converting glucose 6-phosphate (in six
cycles) to CO2 [81, 90].
One of the most important uses of NADPH in cells is to prevent oxidative stress. It
reduces glutathione (GSSG→ 2GSH) via glutathione reductase, which converts reactive
H2O2 into H2O through the action of glutathione peroxidase. This cycle is known as
the redox cycle and is illustrated in figure 1.3 in connection with the pentose phosphate
pathway. In the absence of this cycle, H2O2 would be converted into hydroxyl free radi-
cals, which can attack the cells. By maintaining a reducing atmosphere (a high ratio of
NADPH to NADP+ and a high ratio of reduced (GSH) to oxidized (GSSG) glutathione),
this cycle could prevent or undo oxidative damage to proteins, lipids, and other sensitive
molecules [81, 90].
It was previously mentioned that TPN contains peroxides which may cause oxidative
stress within the cells. Through the pentose phosphate pathway and NADPH production,
the oxidative stress can be decreased by the reduction of glutathione. Glutathione is
the main antioxidant within the cells, especially in the liver, and plays a key role in
balancing the cellular redox potential. Therefore, given the importance of investigating
the possibility of the entrance of glucose into the pentose phosphate pathway, glutathione
levels were measured in the present study.
1.6.3.1 Glutathione
Glutathione is a tripeptide (L-γ-glutamyl-L-cysteinylglycine) and is found widely
distributed and at high levels (0.1-10 mM) in body tissues, especially the liver (5-10
mM). It is one of the key antioxidant that prevents intracellular damage caused by reac-
tive oxygen species such as peroxides and free radicals [91, 92]. Glutathione exists in the
thiol-reduced (GSH) and disulfide-oxidized (GSSG) forms. In a healthy situation, more
than 95% of total glutathione is in the reduced form, and less than 5% exists in the di-
sulfide form. The ratio of GSSG/GSH increases during oxidative stress, and is therefore
usually considered as its indicator. The concentrations of both forms (GSH and GSSG)
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are important in the balancing of the redox potential within the cells. In fact, glutathione
is considered as the buffer of the intracellular redox potential [90–92].
In the presence of glutathione peroxidase, GSH serves as an electron donor and
is oxidized to its disulfide form (GSSG). Once oxidized, glutathione can be reduced
back in the presence of glutathione reductase, using NADPH as an electron donor (fi-
gure 1.3) [90–92].
CHAPITRE 2
HYPOTHESIS AND OBJECTIVES
2.1 Hypothesis
Previous studies on guinea pigs have shown that neonatal exposure to TPN indu-
ced a perturbation of glucose metabolism, leading to a phenotype of energy deficiency
characterized by a lower body weight and a more lazy state. We hypothesize that sup-
plementation of diet, early in life, with a high energetic component such as glucose, will
prevent modifications in body weight and spontaneous physical activity related to the
neonatal infusion of TPN.
2.2 Objectives
2.2.1 General Objective
Assess the mechanisms by which oxidants from TPN contribute to modifications in
the programming of glucose metabolism and how they affect health later in life.
2.2.2 Specific Objective
Assess the impact of neonatal exposure to TPN (first week of life) and early glucose
supplementation (introduced in the third week of life) on the physical (growth rate and
physical activity), biochemical (enzymatic activity of PFK-1 and GK, along with glucose
6-phosphate, glycogen and pyruvate concentrations), and clinical (relative liver weight,
fasting blood glucose, glucose tolerance, triacylglyceride and cholesterol concentrations
in the liver and plasma) phenotypes as well as on the glutathione defenses (levels of
reduced glutathione (GSH), glutathione disulfide (GSSG), and calculation of the redox
potential) in guinea pigs up to their ninth week of life.
CHAPITRE 3
MATERIALS AND METHODS
3.1 Materials
The chemicals that were used in this research study and their sources are presented
in this section.
Tris-hydrochloride (Tris-HCl), ethylenediaminetetraacetic acid (EDTA), nicotinamide
adenine dinucleotide phosphate (NADP), glucose 6-phosphate dehydrogenase (G6PD),
ethylene glycol tetraacetic acid (EGTA), and 1,4-dithiothreitol (DTT) were provided by
the Roche Diagnostics GmbH Co., Mannheim, Germany. Potassium chloride (KCl),
magnesium chloride (MgCl2), glucose, D-fructose 6-phosphate (F6P), adenosine 5′-
triphosphate disodium (ATP), triethanolamine, potassium fluoride (KF), and aldolase
were purchased from SIGMA Life Science Co., Saint Louis, Missouri, USA. Isoflu-
rane and saline were obtained from Baxter Corporation, Deerfield, Illinois, USA. 2-
Mercaptoethanol was provided by BioRad, Hercules, California, USA and xylazine by
Bayer Inc., Calgary, Alberta, Canada. Bovine serum albumin (BSA), ammonium sulfate
((NH4)2SO4), imidazole, methanol, sulfuric acid, and bis-tris were purchased from Fi-
sher Chemical, New Jersey, USA. Potassium hydroxide (KOH) and boric acid were pro-
vided by J.T. Barker Analyzed Reagent Chemical, Austin, Texas, USA. Glyceraldehyde
3-phosphate dehydrogenase and trichloroacetic acid (TCA) were purchased from MP
Biomedical LLC, Solon, Ohio, USA. Sodium hydroxide (NaOH) was provided by A&C
American Chemicals Ltd., Saint Laurent, Quebec, Canada, and silver sulfate (Ag2SO4)
by Laboratoire Mat Inc., Quebec, Canada. Pyruvate was obtained from Dehringer Menn-
hein GmbH, Germany and ketamine from Wyeth Canada, Inc. Markham, Ontario, Ca-
nada.
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3.2 Animal Model
In the present study, three-day-old guinea pigs were employed as a newborn animal
model due to their adequate similarities to the human being. Guinea pigs have striking
similarities to humans in terms of hepatic cholesterol and lipoprotein metabolism [93].
They responses to dietary factors, exercise, and oxidative stress undoubtedly mimic the
human situation [93]. In addition, many of the mechanisms by which guinea pigs regu-
late cholesterol and lipoprotein metabolism as a response to diet are analogous to those
reported in clinical experiments [93]. These trends make them suitable for metabolic
studies [93]. Moreover, guinea pigs experience rapid growth during the third trimester,
can be weaned at the second day of age, and can also develop fatty livers during fetal
life [93–95]. Therefore, they are appropriate models for developmental studies. Finally,
an important corresponding characteristic of newborn guinea pigs and human neonates
is their immature glutathione antioxidant defense systems [94], which makes guinea pig
a suitable model for investigation of the effects of oxidative stress.
3.3 Experimental Set up and Design
The three-day-old male guinea pigs (n=13) were provided by the Charles River La-
boratory, St. Constant, Quebec, Canada. The protocol of this study was approved by the
"Institutional Committee for Good Practice in Animal Research of CHU Sainte-Justine
Research Center, Montreal, Canada" in accordance with the guidelines of the "Canadian
Council on Animal Care". Neonatal guinea pig catheter (1 Fr Silicone Tip, 74 cm 3 Fr
Silicone, 2 Fixed Beads, SA1 Infusion Technologies) was fixed in the jugular vein of all
guinea pig pups on their third day of life. The surgery to fix the catheters was done under
anesthesia with 125 mg/kg-(body weight) ketamine and 10 mg/kg xylazine. The catheter
was exteriorized in the scapular region. The circadian rhythm was adjusted to 12 hours
light and 12 hours darkness. The room temperature was kept at 20◦C.
Animals were randomly assigned to two groups: Control and TPN.
– Control Group: The catheter was closed by a node. Animals had free access to
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regular solid chow (High Fiber Guinea Pig Diet 2041, Harlan Teklad Global, Wil-
mington, DE) with 2.5 kcal/g (table 3.I) from the third day of life until the end of
the study.
TABLE 3.I – 2041 Teklad Global High Fiber Guinea Pig Diet
Macronutrient Information
Nutrient Chow Diet
Energy 1 (kcal/kg diet) 2500
Carbohydrates 2 (g/kg diet) 369 (56% of energy)
Fiber (g/kg diet) 150
Lipids (g/kg diet) 45 (16% of energy)
Amino acids (g/kg diet) 183 (28% of energy)
Methionine (g/kg diet) 2.9
Cyst(e)ine (g/kg diet) 2.7
Zinc (mg/kg diet) 86
Manganese (mg/kg diet) 134
Copper (mg/kg diet) 18
Iron (mg/kg diet) 265
Selenium (mg/kg diet) 0.21
Riboflavin (mg/kg diet) 94
Vitamin E (mg/kg diet) 10.50
Vitamin C (mg/kg diet) 13.8
β -Carotene (mg/kg diet) 46
1) Energy was calculated via the carbohydrates (3.8 kcal/g), amino acids (4 kcal/g), and lipids (9 kcal/g)
from the diets. 2) Carbohydrates exclude fiber.
– TPN Group: For 4 days (3rd to 7th day of life), the guinea pig pups were fed ex-
clusively with TPN via the catheter. Through our experience, we have concluded
that 4 days of exposure to the TPN would be sufficient to investigate the effect
of peroxide. Our lab team tried to increase the number of days ; however, conse-
quently, an increase in the incidence of infiltration was observed. Moreover, the
death rate of animals has increased. The TPN solution was infused at a constant
rate of 220 mL/kg/day and contained 4.8 g/kg/day amino acids + 3.8 g/kg/day li-
pids + 8.7% (w/v) dextrose + 1% multivitamin preparation (MVP) + 1 unit/mL
heparin (table 3.II). The composition of this nutritive solution was close to what
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newborn human infants receive. Heparin is added to the TPN solution to prevent
blood coagulation during fixing the catheter and for its maintenance. At seventh
day of life, TPN was stopped and the animals were fed ad libitum enteral with the
same diet as control group (High Fiber Guinea Pig Diet 2041).
TABLE 3.II – TPN
Macronutrient Information
Nutrient (cal/22ml solution/day) TPN
Energy 9.75
Dextrose 4.26
Lipid 3.66
Amino acids 1.83
Moreover, in order to assess the effect of an early diet enriched in glucose on the
programming of glycolysis later in life, each group was divided into two subgroups
from the 3rd week of life onward. The second week served as a transition period for
the animals to learn how to eat by themselves. Since, Guinea pigs are refractory to a
cafeteria-like diet [96, 97], in order to improve the caloric intake, animals received tap
water with glucose (100 g/L ; similar to sucrose concentration of Coca Cola) whereas the
control subgroup drank regular tap water without any glucose. The animals daily water
consumption was 10 mL per 100 g of body weight. The high concentration of glucose in
the glucose water had some side effects on the guinea pigs, such as painful oral ulcers.
Therefore, the animal facility staff rinsed the mouth of animals with water to prevent this
side effect. Four animals were assigned to each cage due to the space limitation in the
animal facility as well as ensuring an appropriate level of social life for them.
At the 4th week of life, the growth rate, physical activity, blood glucose, plasma
triacylglycerol (TG) and cholesterol were measured. The glucose tolerance curve was
measured at the 8th week of life. We hypothesized that supplementation of diet with a
high energetic component such as glucose would prevent modifications in body weight.
Since, the growth rate is an important characteristic indicating the weight gain rate, al-
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lowing animals to reach their maximum growth rate is important. Based on unpubli-
shed research study of our laboratory (Dr. Lavoie JC), guinea pigs reach their maximum
growth rate between 6th to 9th week of age (figure 3.1). Therefore, animals were sacrifi-
ced at the 9th week of life, after 18 hours of fasting, under anesthesia with isoflurane and
oxygen. Isoflurane was chosen to provide the accurate length and depth of anesthesia.
Isoflurane is usually used with oxygen to prevent hyperventilation. Livers were remo-
ved, weighed, rinsed with 0.9% NaCl, and rapidly minced on the ice bath. Samples were
conserved at −80◦C for further assays. Plasma samples were collected and stored until
determinations.
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FIGURE 3.1 – Guinea pig growth rate versus time (unpublished data from Dr. Lavoie
JC’s laboratory).
Figure 3.2 schematically presents the different stages of the present study as well as
the timeline for the physical, clinical, and biochemical determinations.
3.4 Analytical Measurements
3.4.1 Physical Phenotype Determinations
3.4.1.1 Growth Rate
Body weight was monitored at the beginning of each week. The purpose of this
evaluation was to document the effect of the neonatal TPN and glucose diet on the growth
rate of animals and its impact on their body weight later in life.
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FIGURE 3.2 – The study timeline.
3.4.1.2 Physical Activity
Physical activity was measured at the 4th and 7th week of the animals’ lives as counts
of spontaneous ambulatory activity using the AccuScan infrared instrument (AccuScan
Instruments, Inc., Fusion 2.1, Columbus, Ohio, USA) [98]. Animals did not have access
to chow during the monitoring but water was supplied. Measurements were taken over
a period of 4 hours; however, the results included in this study correspond to the last 2
hours, as the first 2 hours were considered as the adaptation period. The instrument was
equipped with 8 light beams as horizontal lines. Infrared detectors collected the animals’
movements and transferred the information to a computer software which processed the
input signals [98].
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3.4.2 Clinical Phenotype Determinations
3.4.2.1 Fasting Blood Glucose
For this assay, animals had no access to chow for 6 hours. Blood samples were obtai-
ned from the saphenous vein. Blood glucose was measured through the administration
of one peck of blood samples on the strip of a digital glucometer (One Touch ultra Me-
ter, LifeScan Europe, Division of Cilag GmbH International, Switzerland). All recorded
results were displayed in mM values [99]. The remaining blood samples were kept in
K3EDTA-coated tubes and were centrifuged (Beckman Co, Fullerton, CA, USA) at 10
000 RPM for 4 minutes. The plasma (supernatant) was decanted and stored at −80◦C
for triglycerides and cholesterol assays.
3.4.2.2 Glucose Tolerance Test
An intraperitoneal injection of glucose solution (1g/kg-(body weight)) was perfor-
med at the 8th week, after a fast of 18 hours. Measurement of blood glucose of each
guinea pig was performed from the saphenous vein every 30 minutes up to 150 minutes.
Blood glucose was measured using a digital glucometer [99].
3.4.2.3 Plasma Triglycerides and Cholesterol Concentrations
Plasma triglycerides (TG) and cholesterol concentrations were measured at the 4th
and 9th week of guinea pigs’ lives using an enzymatic colorimetric method. For the
plasma TG measurement, a colorimetric commercial kit (Triglycerides GPO-PAP #12016648,
Roche diagnostics, Indianapolis, IN, USA) was used. The kit method is based on the
work by Wahlefeld AW et al. [100] using a lipoprotein lipase from microorganisms for
the rapid and complete hydrolysis of triglycerides to glycerol followed by oxidation to
dihydroxyacetone phosphate and hydrogen peroxide. The resultant hydrogen peroxide
reacts with 4-aminophenazone and 4-chlorophenol under the catalytic action of peroxi-
dase, forms a red dyestuff. The color intensity of the red dyestuff is directly proportional
to the triglyceride concentration and can be measured photometrically. In this study, gly-
cerol (0-2 mM) was used as a standard. For the assay, 1 mL of the kit reagent was added
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to 10 µL of plasma and incubated for 10 minutes at room temperature resulting the red
color solution. The color intensity measurement was performed at a wavelength of 500
nm using a spectrophotometer (DU 640, Beckman Co, Fullerton, CA, USA).
For the plasma cholesterol measurement, another colorimetric commercial kit (Cho-
lesterol CHOD-PAP # 11489437, Roche diagnostics, Indianapolis, IN, USA) was used.
The kit method is base on the work by Allain CC et al. [101] and Roeschlau et al. [102].
Cholesterol is determined enzymatically using cholesterol esterase and cholesterol oxi-
dase. First, cholesterol esters are cleaved by the action of cholesterol esterase to yield
free cholesterol and fatty acids. Then, cholesterol is converted by oxygen with the aid of
cholesterol oxidase to ∆4-cholestenone and hydrogen peroxide. The resulted hydrogen
peroxide forms a red dyestuff by reacting with 4-aminophenazone and phenol under the
catalytic action of peroxidase. The color intensity is directly proportional to the concen-
tration of cholesterol and can be determined photometrically. In our study, cholesterol
(0-4.2 mM) was used as the standard curve. For the assay, the same steps as for TG
measurement were employed. For both assays, the results were expressed in µM.
3.4.2.4 Liver Triglycerides and Cholesterol Concentrations
Hepatic triglycerides (TG) and cholesterol concentrations were measured at the 9th
week of guinea pigs’ lives using the same methods and kits as described for the plasma
in the previous section. However, an additional step for the extraction of the liver lipid
was required to prepare the initial solution for the assay. In our study, the Folch method
was used for the liver lipid extraction [103]. Initially, liver samples (500 mg wet wt.)
were homogenized in two volumes of saline (0.9% NaCl solution) by three passes (10
seconds per pass) in a homogenizer (Polytran Teader, Biospec products Inc, Dermel-
Racine, WI, USA). 100 µL of the homogenate was mixed with 2 mL of Folch solution
(chloroform: methanol 2 :1 v/v) and were agitated for 1 hour, at 4◦C. Subsequently, 400
µL of saline (0.9% NaCl solution) was added to each homogenate sample. Samples were
centrifuged at 2500 × g for 10 minutes at room temperature (25◦C), which resulted in
two separate phases. The upper liquid phase of samples, containing small organic polar
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molecules, were removed by siphoning and the lower solid phase, containing lipids, were
evaporated under a nitrogen stream and re-suspended in 100 µL of Folch and 125 µL of
thesit 20% (v :v), diluted in chloroform. The resultant mixtures were evaporated again
under nitrogen stream, which yields oily residues. The residues were suspended in 1.25
mL distilled water and finally, 50 µL of suspensions were used for the assay. The protein
assay was performed using the Bradford method (see below). The results were presented
as nmol/mg protein.
3.4.3 Biochemical Phenotype Determinations
3.4.3.1 Dosage of protein
Determination of the protein contents of liver fractions and blood cells were perfor-
med by a modification of the Bradford MM et al. method [104], using Bio-Rad reagent
containing 100 mg Coomassie brilliant blue G-250 in 50 mL 95% ethanol and 100 mL
85% (w/v) phosphoric acid. The method is based on the binding of protein with Co-
omassie brilliant blue in acid solution. Hydrophobic and ionic interactions stabilize the
anionic form of the dye, causing a visible color change, which is detected photometri-
cally.
Initially, proteins from liver and blood pellets were solubilized with 1N NaOH (500
mg of liver pellets in 1100 µL of 1N NaOH; 200 µL of blood pellets in 600 µL of
1N NaOH). The solubilizing of samples was performed by incubating at 4◦C for 12
hours. Subsequently, 50 µL of each solution was transferred to the spectrophotometer
cuvette containing 1 mL of Bio-Rad reagent. Cuvettes were incubated for 10 minutes
at room temperature (25◦C). The resulting color intensity was directly proportional to
the concentration of protein and was determined spectrophotometrically at 595 nm. The
protein concentrations were compared to a standard curve of bovine serum albumin (0 -
120 pg/µL).
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3.4.3.2 Glucose 6-Phosphate
The approach used for this assay was the adapted enzymatic method described by
Bergmeyer HU et al. [105]. This method is based on the conversion of G6P to 6-phosphogluconate
and NADPH in the presence of NADP, with the aid of glucose 6-phosphate dehydroge-
nase (G6PD). The formation of NADPH is proportional to the amount of G6P. Using the
spectrophotometer, at 340 nm and knowing the molar extinction coefficient of NADPH
at this wavelength to be 6.22 mM−1cm−1, the concentration of G6P was determined.
For the assay, liver samples (200 mg wet wt.) were pulverized on dry ice with mortar
and pestle, resulting in a powder. Each powdered sample was transferred to a 50 mL tube
containing 300 µL of 3 M cold perchloric acid and 1 mL cold distilled water. Samples
were homogenized by three passes (10 seconds per pass) in the homogenizer. The ho-
mogenates were centrifuged at 5000 × g for 10 minutes at 4◦C. A sample (1 mL) of the
resultant supernatant was mixed with 290 µL of a solution of cold 2M KOH and 0.4 M
imidazole. The supernatants were again centrifuged at 5000 × g for 10 minutes at 4◦C.
The protein assay was performed on the resultant pellets using the modified Bradford
method (section 3.4.3.1). Afterward, 50 µL of the resultant supernatants was transfer-
red to the spectrophotometer cuvette containing 20 µL of 20 mM NADP, 10 µL of 0.5M
MgCl2, 20 µL of 150 mM ATP, and 950 µL of 0.4 M triethanolamine buffer. The absorp-
tion of samples was recorded at 340 nm, 0, 1, and 2 minutes after mixing, and the mean
value calculated (mean absorbance #1). At 2 min, 5 µL of 2.5 µM G6PD was added to
the each supernatant, which enhanced the reaction rate. The absorption of samples was
determined at 340 nm at 6, 7, and 8 minutes, and averaged (mean absorbance #2). To
measure the G6P concentration, the difference between absorbance 2 and 1 was divided
by the molar extinction coefficient of NADPH (6.22 mM−1cm−1) and was reported in
the pmol/mg of protein.
3.4.3.3 Liver Enzyme Activity Assays
– Liver Glucokinase Activity
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Although both hexokinase and glucokinase are present in the liver, glucokinase is
predominant. These enzymes catalyze the production of glucose 6-phosphate from glu-
cose. In the present study, liver glucokinase activity was measured using the method of
Ming-zhi Xu et al. [106] and Ferre T et al. [107]. Based on this method, the extent of
glucokinase activity can be measured through the reduction of NADP in the presence
of G6PD during the conversion of glucose 6-phosphate to 6-phosphogluconate. Since,
the amount of NADP can be measured through a colorimetric method; knowing the mo-
lar extinction coefficient of NADPH at a specified wavelength, the glucokinase activity
could be determined.
For the assay, liver samples (200 mg wet wt.) were homogenized in an ice bath by
three passes (10 seconds per pass) in the homogenizer, in the presence of 2 volumes of
homogenate buffer containing 100 mM tris-HCl, pH 7.5, 5 mM EDTA, 5mM MgCl2,
150 mM KCl and 0.7 µL of 2-mercaptoethanol per mL. Homogenates were centrifuged
at 1400 × g at 4◦C for 20 minutes. Samples of resultant supernatants were centrifuged
again at 12 000 × g for 10 minutes at 4◦C. Supernatants were kept in an ice bath and re-
sultant pellets were suspended in 500 µL of homogenate buffer. The resuspended pellets
were recentrifuged (12 000 × g for 10 minutes at 4◦C) and the resultant supernatants
were combined with the supernatants from the first centrifugation.
The calculation of total enzyme activity of GK was based on the difference between
the glucose phosphorylation capacity in the presence of 100 mM vs 0.5 mM glucose.
Tubes containing 3 mL of reaction buffer (100 mM Tris-HCl, pH 7.5, 0.2 mM NADP,
5 mM ATP, 5 mM MgCl2, 0.2 unit G6PD), containing either 100 mM glucose (high-
glucose) or 0.5 mM glucose (low-glucose) were warmed at 30◦C for 5 minutes. Clear
liver supernatant (20 µL), warmed to room temperature (25◦C) was added into each tube
to start the reaction, which was allowed to proceed for 60 minutes. The rate of formation
of NADPH from NADP was monitored spectrophotometrically from the rate of change
in absorbance at 340 nm. The rate of increase in absorbance achieved in the low-glucose
tube was subtracted from that achieved in the high-glucose tube. Protein content was
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determined by a modified Bradford method (section 3.4.3.1). Liver glucokinase activity
was reported as µmol/min/mg protein.
– Liver Phosphofructokinase-1 Activity
The assay was based on the method of Karadsheh NS et al. [108] and Hamer MJ
et al. [109]. The PFK-1 activity was measured by determining the rate of NADH oxi-
dation and fructose1,6-bisphosphate formation at room temperature (25◦C). Similar to
previously mentioned determinations, the amount of NADH could be measured through
a colorimetric method knowing its molar extinction coefficient at a particular wavelength
(at λ = 340 nm, the molar extinction coefficient of NADH is 6.22 mM−1cm−1). The
PFK-1 activity could be determined based on the rate of NADH oxidation.
Liver samples (300 mg wet wt.) were homogenized by three passes (10 seconds
per pass) in a homogenizer, in 9 volumes of 50 mM triethanolamine, pH 7.35 (20◦C),
containing 1 mM EDTA, 15 mM KF, 2mM MgCl2, and 3 mM EGTA. Homogenates
were centrifuged at 12 000× g for 2 minutes at 4◦C. Supernatants were then centrifuged
at 100 000 × g for 10 minutes at 4◦C to produce a clear extract for analysis of PFK-1
activity.
The total Phosphofructokinase-1 activity was measured at pH 8.1 in an assay sys-
tem (1 mL total volume) which contained 50 mM Tris-HCl pH 8.14, 1 mM fructose-6-
phosphate, 2 mM MgCl2, 1 mM ATP, 0.16 mM NADH, 2.5 mM dithiothreitol (DTT),
5mM (NH4)2S04, 1 mM EDTA, 0.4 unit of aldolase, 2.4 units of triosephosphate iso-
merase and 0.4 unit of glycerol-3-phosphate dehydrogenase. Assay was performed at
25◦C by adding an 0.01 mL aliquot of Phosphofructokinase-containing extract to the
assay system. Absorbance of each sample was read at a wavelength of 340 nm over
a period of 10 minutes. One unit of phosphofructokinase activity corresponded to the
oxidation of 2 µmol of NADH, which is equivalent to the production of 1 µmol of
fructose1,6-bisphosphate/min under these conditions. Protein content was determined
using the modified Bradford method (section 3.4.3.1). The results were expressed in
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terms of µmol/min/mg protein.
3.4.3.4 Pyruvate
A pyruvate assay kit (Bio Vision #K607-100) was used for the pyruvate determina-
tion. The assay is based on the oxidizing of pyruvate by pyruvate oxidase to generate
color. Since the color intensity is proportional to pyruvate content, the pyruvate concen-
tration can be accurately measured.
Liver samples (100 mg wet wt.) were homogenized in an ice bath by three passes (10
seconds per pass) in a homogenizer, initially containing 400 µL pyruvate assay buffer.
The resultant homogenates were centrifuged at 7200 × g for 2 minutes to obtain a clear
pyruvate-bearing supernatant. Using a 96 well plate, individual aliquots of supernatant
(1 µL) were mixed with 50 µL of pyruvate assay buffer (46 µL pyruvate assay buffer,
2 µL pyruvate probe, and 2 µL pyruvate enzyme) in an individual well and incubated
for 30 minute at room temperature, protected from light. The absorbance of each sample
was determined at 570 nm by spectrophotometer. The absorbance values were compared
to those of a series of pyruvate standards (0-8 nmol/well). Protein content was measured
according to a modified Bradford method (section 3.4.3.1). Pyruvate concentrations were
expressed as nmol/mg protein.
3.4.3.5 Glycogen
Determination of the liver glycogen followed the basis Kemp A et al. method [110],
based on the color reaction that occurs by heating a diluted glycogen solution with
concentrated sulphuric acid.
Liver samples (25-75 mg wet wt.) were homogenized in an ice bath by three passes
(10 seconds per pass) in a homogenizer containing 5 mL methanol 80% (v/v). The ho-
mogenates were centrifuged at 3000 RPM for 5 minutes. The resultant supernatants were
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removed. Pellets were ground with 5 mL of deproteinizing solution (5% trichloroacetic
acid and 3.21 mM silver sulphate). The fluids levels were marked on the tubes and the
tubes were covered with glass caps. Although pure glycogen dissolved in the deprotei-
nizing solution, only part of it can be extracted from the liver tissue with a cold solution.
To extract the full complement of liver glycogen, supernatant tubes were heated in a
boiling-water bath for 15 minutes. The tubes were then cooled under running tap water
and were filled up to the mark with the deproteinizing solution to compensate for eva-
poration. Samples were then centrifuged at 3000 RPM for 5 minutes. One mL of 36 N
sulphuric acid was added to 333 µL of each clear supernatant and heated for 6 minutes.
Subsequently tubes were cooled in running tap water. The intensity of the resulting pink
color was proportional to the amount of glycogen and was measured in the spectrophoto-
meter at 520 nm. The glycogen concentration of each sample was compared to a standard
curve for glucose (0-800 µM). Protein content of the homogenate dosage was measu-
red based on a modified Bradford method (section 3.4.3.1). The values were reported in
nmol/mg protein.
3.4.4 Determination of Redox Status
The overall tissue redox status was quantified by the redox status of the couplet of
oxidized glutathione (GSSG) and reduced glutathione (GSH), as described by Schafer
FQ et al. [111]. In our laboratory, the assay of GSH and GSSG levels was based on the
capillary electrophoresis method developed by Lavoie JC et al. [112]. Immediately after
sacrificing animals, liver samples (500 mg wet wt.) were acidified in 5 volumes of iced
and freshly prepared 5% (w/v) metaphosphoric acid and homogenized by 2 passes (10
seconds per pass) in the homogenizer. Metaphosphoric acid reduces the rate of oxidative
processes. Homogenates were centrifuged at 7200 × g for 3 minutes. The resultant pel-
lets and supernatants were frozen at −80◦C until protein and glutathione determination
assays. The assay was performed after the frozen supernatants were thawed and diluted
5-fold in water. The GSH and GSSG from 50 µL supernatant aliquots were separated by
capillary electrophoresis (P/ACETM MDQ Beckman Coulter). The silica capillary had
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an inner diameter of 75 µm and was 50 cm in length. The electrophoresis buffer consis-
ted of 75 mM boric acid and 25 mM Bis-Tris, pH 8.4. Electrophoresis was performed at
a voltage of 18 kV for 10 minutes and samples GHS/GSSG levels were detected at 200
nm. The glutatione-based redox potential was calculated by using the Nernst equation:
Ehc =−240− (59.1/2) log([GSH]2/[GSSG]) mV at 25◦C, pH =7 [111].
3.5 Statistical Analysis
Results of the present study were expressed as mean ± standard error of the mean
(sem). Main effects and interaction effects were tested by ANOVA ([TPN vs. Control]
× [± Glucose diet]) or ([age] × [TPN vs. Control] × [±Glucose diet]). The Bartlett’s
Chi square test was used to assess homoscedasticity. Each group contained at least 3
samples. If a significant interaction occurred between parameters, data was analyzed
according to the parenteral nutrition and control group, glucose-rich-diet or age. A si-
gnificant difference between the TPN and control group would suggest that neonatal
peroxide exposure, in the form of exposure to TPN, induces some form of metabolic
programming. A significant effect of age would suggest that the stage of development
modulates the clinical phenotype. A significant effect of glucose supplementation would
suggest that the nutritional environment is important for the clinical manifestation of the
metabolic phenotype. The threshold of significance was set at p< 0.05.
CHAPITRE 4
RESULTS
According to Barker’s hypothesis of "developmental origin of adult health and di-
sease", several adult disorders can be traced back to the neonatal period. In the present
study, several physical, clinical, and biochemical determinations were made to assess the
impact of neonatal exposure to oxidant molecules and early glucose supplementation on
the modulation of glucose metabolism programming later in life.
Four test groups were compared: 1) "Control" animals were fed regular chow from
the 3rd day to the 9th week of life. 2) "Control + G" were fed regular chow from the
3rd day and supplemented with a diet enriched in glucose from the 3rd week of life. 3)
"TPN" animals received total parenteral nutrition from the 3rd to the 7th day of life and
were fed with regular chow thereafter. 4) "TPN + G" were treated as the "TPN" animals,
but their diet was enriched in glucose from the 3rd to the 9th week. All the animals were
nourished with mother’s milk until their 3rd day of life.
4.1 Physical Phenotypes
The growth rate of animals that had received glucose from the 3rd to 9th week of life
was lower (p < 0.05) than the rate measured in animals that had received water devoid
of glucose (Figure 4.1). The TPN treatment had no significant effect on the growth rate
and there was no interaction between parameters.
The physical activitiy, characterized by the number of movements per hour, mea-
sured at the 4th and 7th week of age, are presented in figure 4.2. All treatments were
without significant effect. Similarly, relative liver weight (figure 4.3) was not affected by
the treatments.
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FIGURE 4.1 – Growth rate during the 3rd to 9th weeks of age. Control: animals fed regular
food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7 of their
lives followed by regular food; G: animals drank sugared water from their 3rd week of
life. The growth rate was lower (p < 0.05) in animals receiving glucose than those not
receiving glucose. Mean±sem, n=3-4 per treatment combination.∗ p< 0.05
FIGURE 4.2 – Physical activity at the 4th and 7th week of age. Control : animals fed
regular food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7
of their lives followed by regular food; G: animals drank sugared water from their 3rd
week of life. There was no significant difference between any treatments at either age.
Mean±sem, n=3-4 per treatment combination.
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FIGURE 4.3 – Relative liver weight at the 9th week of age. Control: animals fed regular
food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7 of their
lives followed by regular food; G: animals drank sugared water from their 3rd week of
life. There was no significant difference between any treatments. Mean±sem, n=3-4 per
treatment combination.
4.2 Clinical Phenotypes
Glucose tolerance results are presented in figure 4.4. None of the treatments affec-
ted blood glucose levels over time after intraperitoneal injection of sucrose. The fasting
blood glucose observed at the 4th and 8th week of life did not differ significantly between
treatments (figure 4.5).
Plasma triacylglycerol (TG) and total cholesterol at the 4th and 9th week are shown
in figure 4.6 (a to d). Cholesterol levels were not significantly different for any treatment
factor. At week 4 there was no effect of any treatment on TG levels (figure 4.6(a)); ho-
wever, at week 9, within the no-glucose treatment TG was higher for the control than the
TPN treatment (figure 4.6(a)); however, this difference was not apparent in the glucose-
treated animals. This long-term impact of TPN (p< 0.05) has been previously reported
by our team [35]. Levels of hepatic cholesterol (figure 4.7) and TG (figure 4.8) showed
no significant differences for any treatment factor.
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FIGURE 4.4 – Blood glucose tolerance at the 8th week of age. Control : animals fed
regular food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7
of their lives followed by regular food; G: animals drank sugared water from their 3rd
week of life. There was no significant difference between any treatments at any time.
Mean±sem, n=3-4 per treatment combination.
C
on
tr
ol
G
T
PN
G
C
on
tr
ol
+
G
T
PN
+
G
4 week
th 8 week
th
C
on
tr
ol
G
T
PN
G
C
on
tr
ol
+
G
T
PN
+
G
F
as
ti
n
g
B
lo
o
d
G
lu
co
se
W
ee
k
s
4
&
8
(m
M
)
0
2
4
6
8
10
12
FIGURE 4.5 – Fasting blood glucose at the 4th and 8th week of age. Control: animals fed
regular food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7
of their lives followed by regular food; G: animals drank sugared water from their 3rd
week of life. There was no significant difference between any treatments at either age.
Mean±sem, n=3-4 per treatment combination.
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FIGURE 4.6 – a) Plasma triacylglycerol at the 4th week, b) Plasma triacylglycerol at the
9th week, c) Plasma cholesterol at the 4th week, and d) Plasma cholesterol at the 9th
week of age. Control: animals fed regular food; TPN: animals fed exclusively by paren-
teral nutrition between day 3 and 7 of their lives followed by regular food; G: animals
drank sugared water from their 3rd week of life. The only significant difference between
treatments was observed in panel (b), where a TPN effect was observed for glucose-free
control treatments (p < 0.05), but disappeared when animals received glucose in their
drinking water. Mean±sem, n=3-4 per treatment combination. ∗: p< 0.05.
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FIGURE 4.7 – Liver triacylglycerol at the 9th week of age. Control: animals fed regular
food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7 of their
lives followed by regular food; G: animals drank sugared water from their 3rd week of
life. There was no significant difference between any treatments. Mean±sem, n=3-4 per
treatment combination.
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FIGURE 4.8 – Liver cholesterol at the 9th week of age. Control : animals fed regular
food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7 of their
lives followed by regular food; G: animals drank sugared water from their 3rd week of
life. There was no significant difference between any treatments. Mean±sem, n=3-4 per
treatment combination.
38
4.3 Biochemical phenotypes
At 9 weeks of age, animals which had received glucose supplementation from their
3rd week of life onwards showed significantly greater GK activity than those receiving
just water (p< 0.05; figure 4.9(a)). However, TPN had no effect on the GK activity.
For PFK activity, a significant interaction (p< 0.05) between (±TPN) and (±glucose),
illustrated in figure 4.9(b), led us to analyze data according to whether animals were
fed glucose-water or not. Data shows that the PFK activity increased in the TPN (vs.
control) treatments when no glucose supplementation occurred (p< 0.05), but no diffe-
rence existed between TPN and control treatments in glucose-treated animals, suggesting
a different effect of glucose for GK and PFK.
The hepatic level of G6P at the 9th week of the guinea pigs’ lives are shown in fi-
gure 4.10. The significant interaction between (±TPN) and (±glucose) for this parame-
ter led us to analyze data according to whether animals drank glucose water or not. The
level of G6P was significantly higher (p < 0.01) in animals exposed to TPN compared
to control groups, but only if the animals received glucose in their diet.
At 9 weeks of age, no significant difference in the level of glycogen (figure 4.11) or
pyruvate (figure 4.12) was apparent between any treatment factors.
4.4 Glutathione status
There was no significant difference between treatments with respect to hepatic concen-
trations of glutathione (GSH) and glutathione disulfide (GSSG) (figures 4.13(a) and 4.13(b),
respectively). However, the GSH/GSSG-derived redox potential (figure 4.14) was more
reduced (less oxidized) (p < 0.05) in the liver of the animals which received (vs. did
not receive) the early glucose supplement in their diet. There was no statistical effect
of TPN. It should be noted that as a marker of oxidative stress, redox potential is more
precise than glutathione. Redox potential is a strong function of GSH level since accor-
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FIGURE 4.9 – a) Glucokinase activity, and b) Phosphofructokinase-1 activity at the 9th
week of age. Control: animals fed regular food; TPN: animals fed exclusively by parente-
ral nutrition between day 3 and 7 of their lives followed by regular food; G: animals drank
sugared water from their 3rd week of life. Glucokinase activity was higher (p < 0.05)
in glucose-fed animals than those receiving plain water. Phosphofructokinase-1 activity
was increased (p< 0.05) in the TPN group without any early glucose supplementation.
Mean±sem, n=3-4 per treatment combination.∗: p< 0.05.
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ding to the Nernst equation, Ehc =−240− (59.1/2) log([GSH]2/[GSSG]) mV at 25◦C,
pH =7 [111], the square value of GSH influences the redox potential. Therefore, a small
change in GSH, not statistically significant, may cause a significant deviation in the re-
dox potential.
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FIGURE 4.10 – Glucose 6-phosphate at the 9th week of age. Control: animals fed re-
gular food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7
of their lives followed by regular food; G: animals drank sugared water from their 3rd
week of life. Glucose 6-phosphate was higher (p < 0.01) in TPN group with early glu-
cose supplementation compared to the other groups. Mean±sem, n=3-4 per treatment
combination.∗∗ : p< 0.01.
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FIGURE 4.11 – Glycogen at the 9th week of age. Control : animals fed regular food
; TPN : animals fed exclusively by parenteral nutrition between day 3 and 7 of their
lives followed by regular food; G: animals drank sugared water from their 3rd week of
life. There was no significant difference between any treatments. Mean±sem, n=3-4 per
treatment combination.
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FIGURE 4.12 – Pyruvate content at the 9th week of age. Control: animals fed regular
food; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7 of their
lives followed by regular food; G: animals drank sugared water from their 3rd week of
life. There was no significant difference between any treatments. Mean±sem, n=3-4 per
treatment combination.
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FIGURE 4.13 – a) Glutathione (GSH), and b) Glutathione disulfide (GSSG) at the 9th
week of age. Control: animals fed regular food; TPN: animals fed exclusively by paren-
teral nutrition between day 3 and 7 of their lives followed by regular food; G: animals
drank sugared water from their 3rd week of life. There was no significant difference
between any treatments. Mean±sem, n=3-4 per treatment combination.
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FIGURE 4.14 – Redox potential at the 9th week of age. Control: animals fed regular food
; TPN: animals fed exclusively by parenteral nutrition between day 3 and 7 of their lives
followed by regular food; G: animals drank sugared water from their 3rd week of life.
The redox potential in animals receiving glucose in their water was more reduced (less
oxidized) (p< 0.05) than in animals drinking glucose-free water. Mean±sem, n=3-4 per
treatment combination. ∗ : p< 0.05.
CHAPITRE 5
DISCUSSION
To our knowledge, the present study is a pioneer work investigating the interaction
between neonatal exposure to TPN and early glucose supplementation on the program-
ming of glucose metabolism. Our research study illustrates several alterations of physi-
cal, biochemical, and clinical phenotypes during the developmental stage of guinea pigs
before reaching their maximum growth rate (9 weeks of age ; figure 3.1). Kleiber N et al.
explored the connection between neonatal exposure to TPN and the modulation of lipid
and glucose metabolism in guinea pigs at 13 weeks of age [35]. However, it is unclear
whether the observed alterations stem from the period prior to or following their maxi-
mum growth rate. The present study follows in the footsteps of the findings of Kleiber
N et al. [35] who demonstrated the impact of neonatal TPN on energy metabolism later
in life, up to 13 week of age. We were interested to know if these manifestations occur-
red earlier in life. Since Kleiber concluded that neonatal TPN induces a modification of
glucose metabolism later in life, leading to a phenotype of energy deficiency, a second
objective was to know if introduction of an early glucose-enriched diet could alter this
phenotype.
In our experimental design, no modification of parameters was observed at the 4th
week of life, whereas by the 9th week, modification in several components of glycolysis
were documented, as well as modification of plasma TG and redox potential. For some
of these modifications, there were significant interactions with glucose diet.
To understand the mechanisms by which glycolysis may be perturbed, the activity of
two key enzymes of this pathway (glucokinase and phosphofructokinase-1) was investi-
gated. There were no significant differences in GK activity (figure 4.9(a)) between ani-
mals receiving TPN or standard chow for either glucose-supplemented or glucose-free
water treatments ; however, glucose supplementation gave raise to significantly higher
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GK activity than it’s absence. In contrast, Kleiber N et al. observed greater GK activity
in the TPN (vs. standard chow) group at the animals’13 week of life [35]. These obser-
vations could suggest a probable effect of TPN on the modulation of GK activity later
in life after reaching the maximum growth rate level, i.e (after 9 days). Several studies
have shown glucokinase is sequestered in the nucleus of the hepatocyte [81, 113, 114],
and released when the cytoplasmic glucose concentration increases [113–120]. In the
present study, showing the same behavior, the GK activity of groups that received a
glucose-enriched (vs. glucose-free) diet, increased at the 9th week. This illustrates the
modulation of GK activity by postnatal glucose supplementation, thereby initiating the
normal steps of glycolysis.
As discussed previously, GK is the hepatic enzyme that allows hepatocytes to conti-
nue phosphorylating of glucose into G6P during the rise in glucose concentration [121].
In this study, a greater production of G6P is expected considering the higher GK acti-
vity in groups that received a glucose-enriched diet [121]. Statistical analysis confirms
this, but only for the group exposed to TPN. Accordingly, one may wonder about this
high level of G6P accumulation. In fact, several studies have observed that G6P is at
the crossroads of carbohydrate metabolism in the liver [95]. It may have several ma-
jor fates and enter different metabolic routes depending on the metabolic demands of
the organism [81]. The liver directs the flow of G6P into different pathways through
the action of several allosteric regulatory enzymes and the hormonal regulation of en-
zyme synthesis and activity [81, 121–123]. G6P can be dephosphorylated via the enzyme
glucose 6-phosphatase [81, 113]. This reaction converts G6P to free glucose, which is
exported to replenish blood glucose and provide adequate energy for the brain and other
tissues [81, 113]. In the present study, in order to verify if G6P entered this pathway, the
blood glucose level of animals was measured, but no significant differences were obser-
ved.
Another possible fate of glucose 6-phosphate is its conversion to hepatic glycogen,
assuming that the body does not require blood glucose immediately [81, 114, 117, 118].
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In order to determine if G6P in animals that have a glucose-enriched diet has entered
into glycogenesis pathway one can measure the amount of liver glycogen, as was done
in the present study. Measurements showed that no treatment had a significant effect on
the amount of glycogen.
On the other hand, several investigations have confirmed that glucose-6-phosphate
can also be broken down through glycolysis and decarboxylation of the pyruvate via
the pyruvate dehydrogenase reaction [35, 120]. However, the level of pyruvate mea-
sured in the present study showed no significant differences between groups. In addi-
tion, many studies have indicated that pyruvate can be converted to acetyl coenzyme
A [81, 113, 120]. This component could be oxidized through the citric acid cycle to
produce energy, with ensuing electron transfer and oxidative phosphorylation yielding
ATP [81, 113, 120]. Normally fatty acids are the preferred fuel for energy production in
the liver [81]. Acetyl coenzyme A may also serve as the precursor of fatty acids or cho-
lesterol [81, 113, 120]. Such fatty acids are incorporated into triacylglycerol and phos-
pholipids [81]. Much of the lipid synthesized in the liver is transported to other tissues
through the mechanism of blood lipoproteins. In our investigation, the concentration of
plasma and hepatic cholesterol, as well as that of hepatic TG was measured ; however,
no significant differences were apparent between diets with or without TPN for animals
receiving early glucose supplementation. The monitoring acetyl coenzyme A will be the
domain of future studies.
The final fate of glucose 6-phosphate may be its entrance into the pentose phos-
phate pathway [81]. A NADPH-powered reduction is required for the biosynthesis of
fatty acids and cholesterol [122]. The plasma and hepatic cholesterol measurement in
our study showed no significant differences between any treatments. NADPH is also an
essential cofactor in the detoxification and elimination of many metabolites in the li-
ver [122]. Cells require NADPH for reductive biosynthesis or to counter the damaging
effects of oxygen radicals [81, 122]. The detoxification of peroxides depends directly
on the availability and the regeneration of NADPH. Within cells and tissues, the pen-
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tose phosphate pathway appears to be the predominant deriver of the regeneration of
NADPH [124–127]. Kussmaul L et al. illustrated that detoxification of peroxide, which
is a metabolic process, is linked to the availability of glucose as a metabolic substrate
[145] and the hydride donor for the regeneration of NADPH needed in the reduction of
glutathione (GSSG→ 2GSH) by glutathione reductase [127].
Our results showed a reduction of the redox potential at the 9th week of age in groups
that received glucose, independently of whether they received neonatal TPN or not. Re-
dox potential is essentially associated with the biological status of the cell and could
influence several metabolic pathways. For instance, in several pathways, the thiol status
is important for its function. This status is strongly influenced by the redox potential
of the cell. In general, pathways regulated by phosphorylation are susceptible to be in-
fluenced by the redox potential. These results support the hypothesis of the entrance of
G6P into the pentose phosphate pathway. By reducing GSSG to GSH, via glutathione
reductase, NADPH contributes greatly to a shift in the redox potential toward a more re-
duced status. Therefore, it may prevent or undo the oxidative damage of proteins, lipids,
and other sensitive molecules [81, 122]. NADPH likewise protects cells from oxidative
damage from hydrogen peroxide (H2O2) and superoxide free radicals [81, 122] through
the normal detoxification process previously described in section 1.6.3.
In the present study, no significant difference was observed in glucose tolerance at
the 4th or 8th week of life for any treatment. These results indicate that there was no
resistance to insulin, a major energy metabolism modulator [35]. We did not measure
the concentration of insulin given the unavailability of a commercial antibody for guinea
pig insulin [35]. However, higher PFK activity and lower plasma TG were observed in
animals that received TPN without any glucose supplementation, although it could not
confirm insulin dysregulation [35]. In the Kleiber N et al. study, a significant difference
existed in glucose tolerance in 13-week-old guinea pigs [35]. These findings suggest
that the modulation of glucose tolerance might be linked with the age and stage of deve-
lopment. However, it may occur after reaching the maximum level of growth rate, at or
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around the 9th week. At this time PFK activity increased in those animals which recei-
ved TPN only, whereas in the Kleiber N et al. study its activity decreased. This reveals
a perturbation of PFK activity caused by an early exposure to oxidant molecules and its
direct correlation with the developmental stage of the animals’ life. The high activity of
PFK observed in our experimental study might have been expected to alter the amount
of pyruvate ; however, this was not the case. The activity of enzymes involved in lipid
metabolism and related metabolic pathways remains to be investigated.
In the present study, several physical determinations were examined in order to ob-
serve any correlation between a neonatal exposure to oxidant molecules alone or in com-
bination with an early diet enriched in glucose (as a source of energy) and physical
phenotype alterations later in life. One of these physical phenotypes was the animals’
growth rate. The growth rate of guinea pigs having received a glucose-enriched diet was
lower than that of guinea pigs having received glucose-free water. This runs counter
to the study’s hypothesis. One of the probable reasons is that a high concentration of
glucose in water caused mouth ulcers in this experimental population, thus disabling or
reducing normal food intake. However, this complication was quickly corrected by the
action of the personnel of the animal facility that regularly rinsed the mouth of animals
with sugar-free water. After the TPN/no TPN treatment period, all animals had free ac-
cess to the chow food. Other studies have demonstrated suppression of food intake when
the level of glucose entering the brain rose [128]. Therefore, the groups that received
glucose supplementation likely experienced a decreased appetite, and therefore did not
take in sufficient calories for growth.
Nevertheless, according to the Lucas hypothesis of "accelerated growth," increasing
the growth rate could cause adult obesity. Lucas explains the association between faster
early postnatal growth in infants who have a delay in their growth rate during their intrau-
terine life and an increased risk of metabolic syndrome indicators later in life [9, 60, 61].
According to Barker and Lucas, the origin of several adult diseases can be traced back to
the neonatal and postnatal stage of life. One of the risk factors in programming of adult
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disease is the postnatal growth rate [9]. Pylipow M et al. studied 463 seven-year old adult
human born with low birth weight. They observed that an early rapid postnatal growth
rate led to a greater body weight later in life [58], while a lower growth rate did not trig-
ger obesity later in life in the same population. Isganaitis E et al., performed a low-birth
weight mouse study design demonstrating the effects of postnatal growth rate in meta-
bolic diseases later in life [129]. They observed that high postnatal growth rate affected
the adipose tissue’s lipogenic gene expression, resulting in larger adipocytes [129]. In
addition, in their rat model, Desai M et al. observed that accelerated growth altered the
metabolic parameters in response to a high-fat diet, as well as increased weight and per-
centage of body fat [59] later in life. Therefore, the result of a lower growth rate due to
the early addition of glucose to the diet of animals that received neonatal oxidant mole-
cules may modify metabolic disorders later in life.
The body weight of guinea pigs exposed to TPN in the Kleiber N et al. study de-
creased by the 13th week of life [35]. In the present study, this phenotype showed no
significant difference at the 9th week in the TPN group without glucose supplementation.
These observations might suggest the programming that leads to alterations in physical
phenotypes later in life may occur after the 9th week. We measured physical activity as
a physiologic marker of energy expenditure [130]. There was no significant difference
in this physical phenotype at either 4th or 7th week of life. In the Kleiber N et al. study
the decrease in physical activity was observed in the 13th week of life in animals that re-
ceived early TPN. These results suggest that modulation of this phenotype may depend
on the stage of the animals’ development. Likewise, in the present study, the physical
activity of the groups that received a glucose-enriched diet did not change. These results
suggest that decreasing the level of plasma TG may affect the physical activity pheno-
type modulation and the perturbation of lipid and glucose metabolisms, thus inducing
energy production later in life [35].
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5.1 Limitations
This study was subject to several limitations, including :
(i) the sample size of the study was small mainly due to the limited funding of the
welcome laboratory. Statistically, small sample sizes increase the standard deviation
and prevent obtaining a greater statistical power to demonstrate a difference when it
exists [131].
(ii) several studies demonstrated that when the level of glucose entering the brain rises,
food intake is suppressed [128]. Therefore, the high concentration of glucose in the
present study might prevent the animals’ normal and proper food intake. Moreover, the
free accessing of animals to the chow might limit the precise body growth rate observed.
(iii) the present study was performed on male guinea pigs. Choi et al. in their rat study
design demonstrated that metabolic programming alterations depend on the sex and can
increase metabolic risk factors more in adult males than females [132]. They showed
that cholesterol levels and liver TG content were lower in females compared to males.
The Chessex P et al. study on preterm infants (< 1000 g) receiving TPN containing dif-
ferent amounts of peroxides, demonstrated that among infants who received higher levels
of peroxide, only females had a higher blood pressure and cardiovascular effects [77].
These observations support the notion that the metabolic programming might depend on
the gender. Therefore, the results of the present study may not be generalized to females.
(iv) Due to the space limitation of the animal facility, four animals were assigned to each
cage. Therefore, it was not possible to measure the food consumption of guinea pigs
individually. Besides, since within the cages, four animals are from different groups,
averaging of the food consumption per cage would not be useful. For the future studies,
we suggest that animals from the same group be assigned to each cage.
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5.2 Future Studies
Regan FM et al. suggested that neonates fed with a high carbohydrate diet might
suffer from greater growth rate and a greater reduction in insulin sensitivity later in
life [133]. Insulin resistance was observed early in the pathogenesis of adult metabolic
diseases, and an isolated reduction in insulin sensitivity had been reported in low birth-
weight neonates and children [133]. An explanation for the association between low
birth-weight infants and later metabolic disease in adulthood is early impairment of in-
sulin sensitivity. It may increase obesity and induce insulin resistance in adulthood [133].
Furthermore, they demonstrated that TPN with high amounts of carbohydrate may im-
pair insulin sensitivity in later life of infants and may lead to obesity as well as obesity-
related disorders such as high blood pressure [133]. In the prospective studies, the proper
concentration of glucose diet should be measured to prevent the probable alterations of
several physical and biochemical phenotypes, such as BMI and body fat, later in life [45].
In future studies, experimental designs investigating the impacts of high caloric diet
on clinical phenotype in animals exposed to oxidative stress in their early life should be
improved. The activity of several enzymes that contribute to the pentose phosphate path-
way and lipid metabolism pathway as well as the amount of acetyl coenzyme A should
be determined. Finally, in order to generalize the results, the sample size needs to be
increased in the prospective studies.
5.3 Conclusion
Diet strategies should be investigated in order to prevent the programming of adult
metabolic disorders associated with neonatal oxidative stress. Infants, who are born pre-
maturely (<28 weeks of gestation) need TPN for growth and development [80]. The
complete photo protection of this solution against ambient light, which catalyzes the
peroxide generation, is clinically impossible [71]. As a result, several oxidant mole-
cules [18, 19, 22, 24, 133] are generated, thus leading to neonatal oxidative stress [134].
52
This early mode of nutrition has several short and long-term effects on the clinical, physi-
cal, and biochemical phenotypes in this fragile population [27–29, 35, 77–80, 134–136].
These modifications all depend on the stage of development.
The neonatal and postnatal period may be a starting point of adult diseases [46].
Present study suggests that the quality of TPN and nutrition have an impact on metabo-
lism later in life. Parenteral nutrition has several long-term effects on the programming
of lipid and carbohydrate metabolism. For example, the level of plasma triglyceride is lo-
wer among animals that received neonatal TPN and may lead to the alteration of energy
metabolism later in life [35]. The activity of enzymes involved in the glycolysis pathway
shifts at various stages of development. The present study indicates that the quality of
neonatal and postnatal diets may also have an effect on the development of an oxidative
defense system [46, 136]. A glucose-enriched diet may improve the immature antioxi-
dant defense system of this fragile population by increasing NADPH regeneration [124–
127, 137]. This has beneficial effects on cell detoxification, especially with respect to
oxidative stress, and can thus maintain cell integrity [127]. The early glucose-enriched
diet may improve the glucose metabolism pathway, thereby preventing the reduction
of plasma triglyceride later in life. Moreover, this early supplementation has positive
effects on the physical phenotypes, thus decreasing growth rate acceleration. This reduc-
tion may also decrease the risk of metabolic syndrome indicators [39, 42, 60, 61] and
adult coronary heart diseases, such as hypertension, and type II diabetes [2, 4, 8].
In summary, results suggest that the diet supplementation of glucose in guinea pigs
exposed to oxidative stress may stimulate the glycolysis pathway, shift the redox po-
tential towards more a reduced status, as well as induce several alterations in physical,
biochemical, and clinical phenotypes later in life.
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